Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.10.23 | HOOKIPA Pharma Inc.: HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023 | 244 | GlobeNewswire (Europe) | 42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting-doubling historical ORR reported with pembrolizumab... ► Artikel lesen | |
22.10.23 | Sutro Biopharma, Inc.: Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 | 205 | GlobeNewswire (Europe) | - Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRa... ► Artikel lesen | |
22.10.23 | Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant | 277 | GlobeNewswire (Europe) | Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis... ► Artikel lesen | |
22.10.23 | Revolution Medicines, Inc.: Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 | 336 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced... ► Artikel lesen | |
22.10.23 | Sanofi: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) | 620 | GlobeNewswire (Europe) | Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Late-breaking presentation at ACG 2023 showed... ► Artikel lesen | |
22.10.23 | Agillic A/S: Agillic joins partner Immeo in supporting the 'Knæk Cancer' (fight cancer) fundraising campaign | 474 | GlobeNewswire (Europe) | Cancer affects one out of every three people in Denmark before the age of 75, making cancer something that touches most, if not every Dane. Whether as a patient, next of kin, friend, or colleague, we... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 4.238 |
NVIDIA | 3.073 |
TUI | 2.378 |
GAMESTOP | 2.334 |
BAYER | 1.753 |
NEL | 1.693 |
RHEINMETALL | 1.495 |
BYD | 1.307 |
DEUTSCHE LUFTHANSA | 1.158 |
TESLA | 947 |
VOLKSWAGEN | 831 |
APPLE | 718 |
CARL ZEISS MEDITEC | 715 |
SUPER MICRO COMPUTER | 708 |
BASF | 673 |
DEFI TECHNOLOGIES | 630 |
SNOWFLAKE | 625 |
AIXTRON SE | 619 |
COMMERZBANK | 617 |
THYSSENKRUPP | 617 |
PORSCHE SE | 589 |
CAVENDISH HYDROGEN | 564 |
MERCEDES-BENZ | 521 |
DEUTSCHE BANK | 519 |
ALLIANZ | 508 |